The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | The impact of clonal features on the survival of patients with non-cardiac AL amyloidosis
Paolo Milani
• 7 Sep 2022
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, comments on the impact of clonal features on the diagnosis, overall survival (OS), and hematologic event-free survival (EFS) of patients with non-cardiac AL amyloidosis, and highlights the importance of using this information to guide treatment decisions. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
Disclosures
Janssen
